Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PI-88 in Adjuvant Treatment of Post-resection Hepatocellular Carcinoma
NCT00568308Phase 3Terminated
- Sponsor
- Progen Pharmaceuticals
- Start
- Dec 2007
- Primary completion
- Jul 2008
- Modality
- Bivalent/Multivalent Binders
- Countries
- 10
01
Overview
A Phase 3 trial of Muparfostat in hepatocellular carcinoma (HCC), sponsored by Progen Pharmaceuticals. Started Dec 2007; status: terminated.
02
Drugs
Muparfostat
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00568308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00568308.